Astellas Pharma Inc.'s novel oral anemia drug roxadustat has become the first in its class to be approved in Japan and looks set to reach this potentially large market ahead of multiple close rivals.
The inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) was approved as Evrenzo for the treatment of renal anemia associated with...







